Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.
Don't Overlook Exelixis (EXEL) International Revenue Trends While Assessing the Stock
Explore how Exelixis' (EXEL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
EXEL beats on Q2 earnings but misses revenues as lower collaboration income offsets strong Cabometyx sales growth.
Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript
Exelixis, Inc. (NASDAQ:EXEL ) Q2 2025 Earnings Conference Call July 28, 2025 5:00 PM ET Company Participants l - Corporate Participant Amy C. Peterson - Executive VP of Product Development & Medical Affairs and Chief Medical Officer Christopher J.
Exelixis (EXEL) Beats Q2 Earnings Estimates
Exelixis (EXEL) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.84 per share a year ago.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
EXEL investors eye Cabometyx sales and zanzalintinib trial results ahead of Q2 earnings release on July 28.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings
Get a deeper insight into the potential performance of Exelixis (EXEL) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
